Our previous study showed that lungs infected by Pseudomonas, a gram-negative bacteria, produce prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2), the two major prostanoids generated by cyclooxygenase-2 (COX-2), and that the ratio of PGD2 and PGE2 can affect the outcome of the bacterial lung infection. In this study, we sought to uncover the mechanism that determines the ratio of PGD2 and PGE2 produced in lung inflammation. When treated with lipopolysaccharide (LPS), primary alveolar macrophages, extracted from mouse lung, more PGE2 was produced than PGD2, whereas MH-S, a murine alveolar macrophage cell line, produced more PGD2 than PGE2 in a similar experiment. Western blot analyses showed that the kinetics of COX-2 expression in both cell types is similar and epigenetic silencing of COX-2 expression did not affect expressions of lipocalin-PGD synthase (L-PGDS) and PGE synthase (mPGES-1), major enzymes synthesizing PGD2 and PGE2 in inflammation, respectively, indicating no effect of COX-2 on expressions of the two enzymes. Expressions of L-PGDS and mPGES-1 were also similar in both cell types, suggesting no effect of the two key enzymes in determining the ratio of PGD2 and PGE2 in these cells. A single intraperitoneal injection of LPS to C57BL/6 mice induced COX-2 expression and, similar to alveolar macrophages, produced more PGE2 than PGD2 in the lung. These results suggest that the differential expressions of PGD2 and PGE2 in the lung reflect those in alveolar macrophages and may not be directly determined by the enzymes responsible for PGD2 and PGE2 synthesis.
Introduction
Alveolar macrophages play a key role in lung immunity, as evident in the experiment that treatment of mice with liposomal clodronate depletes macrophages in the lung, which results in impairment of mounting inflammatory response and of clearing bacteria from the lung [2, 5, 14] . Macrophages recognize bacterial pathogens via receptors for pathogen-activated molecular patterns, such as Toll-like receptors, and trigger a series of inflammatory responses by producing various cytokines that are essential for neutrophils recruitment and other immunologic effector functions of macrophages [9] . The inflammatory response normally confines bacterial infection.
Macrophages are the major cell type responding to lipopolysaccharide (LPS) [3] , one of the major bacterial factors that trigger inflammation, and this feature is in part due to Toll like receptor 4 (TLR4) that is highly expressed in macrophages [15, 16, 18, 27] . Binding of LPS to TLR4 initiates Toll/IL-1 receptor (TIR)-mediated signaling, which activates inhibitory κB kinase (IKK) and mitogen-activated protein kinases (MAPKs). Activation of these kinases increases transcriptional activities of NF-κB and AP-1, respectively, resulting in expression of various inflammatory genes including cyclooxygenase-2 (COX-2) [4, 10] . COX is the rate-limiting enzyme in the biosynthesis of prostanoids [8] . Two isoforms of COX have been identified: COX-1 and COX-2. The former is constitutively expressed in most of cell types, and the latter is inducible by many pro-inflammatory stimuli. COX metabolizes arachidonic acid to produce prostaglandin H2 (PGH2), which is used as the common precursor for the synthesis of prostanoids including prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2) [7] . Conversion of PGH2 to PGD2 is mediated by two distinctive enzymes, lipocalin-type prostaglandin D synthase (L-PGDS) and hematopoietic isotype (H-PGDS). In macrophages, H-PGDS is constitutively expressed but L-PGDS is inducible by inflammatory stimulus such as LPS [12] . On the other hand, conversion of PGH2 to PGE2 is mediated by three iso-forms of PGE synthases: cytosolic PGE synthase and type 1 (mPGES-1) and type 2 membrane-bound PGE synthases (mPGES-2) [23] [24] [25] . While the expression of cytosolic PGE synthase is constant, expressions of mPGES-1 and mPGES-2 are inducible by various stimuli [6, 22] . Among them, mPGES-1 is considered as the major enzyme responsible for PGE2 produced in the inflammatory milieu [22] .
It is well documented that prostanoids are involved in regulation of inflammation and host defense against bacterial and viral infections. For instance, we have shown that PGD2 enhances clearance of Pseudomonas infected to the lung [12] . On the other hand, PGE2 favors Pseudomonas infection by impairing the clearance of Pseudomonas from the lung [20] . Therefore, defining the mechanism of regulating the ratio of PGD2 and PGE2 could yield therapeutics that control acute and chronic bacterial infections. In this study, we sought to determine the mechanism that controls the ratio of the two prostanoids, PGD2 and PGE2. To examine the effects of enzymes synthesizing the two prostanoids on the production of the two molecules, we isolated primary macrophages from the lung, alveolar macrophages, and analyzed them in expressions of the enzymes and productions of PGD2 and PGE2 after LPS treatment, along with a well-established alveolar macrophage cell line, MH-S. Using an acute lung injury mouse model, we compared the profile of PGD2 and PGE2 in the lung with that of primary alveolar macrophages. Our results showed that the differential productions of PGD2 and PGE2 do not result from differences in the expression of the cognate enzymes, and suggest that alveolar macrophages play a key role in determining the ratio of PGD2 and PGE2 in the lung.
Materials and Methods
Reagents TLR4-specific Escherichia coli LPS was purchased from Alexis Biochemical (San Diego, CA). Antibodies for COX-2, mPGES-1, and mPGES-2 antibodies were obtained from Cayman Chemical, and antibody for actin was purchased from Santa Cruz Biotechnology.
Animals
Male wild type mice (C57BL/6) weighing 20-28 g were used for experiment. Animal experiment was performed per the protocol approved by the Pusan National University Institutional Animal Care and Use Committee. 
Total RNA and semi-quantitative RT-PCR
Total RNA from the lung was isolated by using QIAGEN RNeasy ® mini kit (Qiagene, Hilden, Germany). Three micrograms of total RNA were reverse-transcribed by M-MLV reverse transcriptase (Promega, Madison, WI, USA), and single-stranded cDNA was amplified by PCR with a set of specific primers noted as follows: the forward and the reverse primers for COX-2 were 5'-CCCAGAGCTCCTTTTCA ACC-3' and 5'-AATTGGCACATTTCTTCCCC-3', respectively; and the forward and reverse primers for GAPDH were 5'-GGAGCCAAAAGGGTCATCAT-3' and 5'-GTGATG GCATGGACTGTGGT-3', respectively. For PCR, TaqPCRx DNA polymerase (Invitrogen, Carlsbad, CA, USA) was used, and the reaction was carried out in an initial denaturation at 95°C for 5 min followed by 30 cycles of denaturation for 40 sec at 95°C, annealing for 40 sec at 55°C, and extension for 50 sec at 72°C, along with a final extension for 7 min at 72°C. The resultant of PCR was analyzed by running on 1.5 % agarose gel, which was visualized under UV light.
Statistical analysis
For comparison among groups, paired or unpaired T tests and one-way analysis of variance (ANOVA) tests were used (with the assistance of InStat, Graphpad Software, Inc., San Diego, CA) (p values <0.05 are considered significant). All experiment was performed at least three times independently.
Results

Differential productions of PGD2 and PGE2 in alveolar macrophages
To understand the mechanism that determines differential productions of PGD2 and PGE2 in bacterial lung infection, we first examined the profiles of PGD2 and PGE2 in alveolar macrophages. For the study, we used primary alveolar macrophages extracted from the mouse lung and a well-studied, murine alveolar macrophage cell line, MH-S cell. These cells were treated with highly purified, TLR4 specific LPS to avoid stimulating other signaling cascades. At 16 hr after the treatment of MH-S cells with LPS (100 ng/ml), the cell culture media was collected to measure PGD2 and PGE2 excreted to the media. As shown in Fig. 1 A, LPS treatment induced productions of PGD2 and PGE2, in which the amount of PGD2 was higher than PGE2. To test whether this is also the case in primary alveolar macrophages, we obtained macrophages from the lung by performing bronchoalveolar lavage of the mice, and treated them with LPS similar to were treated with TLR4 specific LPS (100 ng/ml) for 16 hr, and PGD2 (dark bar) and PGE2 (gray bar) in the cell culture media were measured as described in materials and methods. Each bar represents the mean value of three mice±SEM (* and **, p<0.05 compared with each controls).
Effects of COX-2 expression on the ratio of PGD2 and PGE2 in alveolar macrophages
Since COX-2 is the major enzyme responsible for the production of PGD2 and PGE2 in macrophages activated by inflammatory stimuli [8] , we tested whether the differential expressions of PGD2 and PGE2 result from differences in induction of COX-2 expression. MH-S cells and primary alveolar macrophages were treated with LPS (100ng/ml) for various periods up to 12 hr, and the expression of COX-2 was measured by Western blot analysis. As shown in Fig. 2 , LPS treatment of MH-S and primary alveolar macrophages induced COX-2 expression, and it appears that there was no significant time difference in the induction of COX-2.
Although no apparent differences in the kinetics of COX-2 induction between MH-S and primary alveolar macrophages were detected, it is possible that minor differences in the amount of COX-2 protein contribute to the differences in the amount of PGH2, leading to the differential productions of L-PGDS and mPGES-1 and accordingly PGD2 and PGE2, respectively. To test this possibility, we suppressed the expression of COX-2 by using siRNA and tested whether the suppression of COX-2 affects the expressions of L-PGDS and mPGES-1 (Fig. 3) . MH-S cells were transfected with either control or COX-2 specific siRNA, and the transfected cells were treated with LPS for 24h to induce COX-2 expression.
Western blotting for COX-2 shows that siRNA effectively suppressed COX-2 expression (top panel). However, in similar analyses for L-PGDS and mPGES-1 in the COX-2 suppressed cells, we found no significant changes in expression levels of L-PGDS and mPGES-1 (middle and bottom panels, Fig. 2 . COX-2 expression in alveolar macrophages. MH-S cells (top panel) and primary alveolar macrophages (middle panel) were treated with LPS (100 ng/ml) for various time points. At the indicated time point, the cells were harvested, and the total proteins were separated by SDS-PAGE and analyzed by Western blot for COX-2 expression. Actin was similarly analyzed for internal controls. Shown was actin in primary alveolar macrophages (bottom panel). Higher PGE2 production in the lung inflamed by LPS Finally, we examined the ratio of PGD2 and PGE2 in the lung inflamed by LPS. C57BL/6 mice received an I.P injection of LPS (3 μg/g), and at 24hr after LPS injection the mice were sacrificed and the lungs were extracted for the analysis of RNA and the measurement of prostanoids. At first, we determined whether LPS administration induces inflammation in the lung by measuring COX-2 expression. RT-PCR results, as shown in Fig. 5A , showed that LPS treatment of the mice elicited COX-2 expression in the lung, indicating that lung inflammation took place. Next, we measured PGD2 and PGE2 from the lung tissue. As shown in Fig.  5B , LPS treatment induced productions of PGD2 (hatched bars) and PGE2 (gray bars), and, similar to alveolar macrophages, more PGE2 was produced than PGD2. This imparity in production of PGD2 and PGE2 was also similarly observed at early time points, 8 hr and 12 hr (data not shown). Together with the results of Fig. 1B , these results show that there was a possible correlation between alveolar macrophages and the lung in productions and the ratio of PGD2 and PGE2.
Discussion
Prostaglandins are involved in regulation of inflammation, and PGD2 and PGE2 are the major prostanoids involved in acute lung inflammation and host defense against various bacterial challenges. However, the effects exerted by these prostanoids are not well understood because the effects are complex and dependent on the specific inflammatory milieu.
Our previous studies, for instance, showed that while PGD2
ameliorates Pseudomonas infection to the lung [12] , PGE2 exacerbates Pseudomonas infection [20] . These results suggest that understanding the mechanism that determines the differential productions of PGD2 and PGE2 by bacterial infection can lead to new therapeutics for the treatment of chronic Pseudomonas lung infection that is prevalent in cystic fibrosis patients. Therefore, we have interested in uncover-ing the mechanism by which the ratio of PGD2 and PGE2
is regulated in the lung. In this study, we explored a possible mechanism by using TLR4-specific LPS as an inflammatory stimulus. Our results showed that the enzymes responsible for the synthesis of PGD2 and PGE2 do not directly affect the ratio of PGD2 and PGE2 in the macrophages and that, similar to higher production of PGE2 in primary alveolar macrophages, the lung produces more PGE2 over PGD2.
These results suggest that alveolar macrophages are important in determining the ratio of PGD2 and PGE2 in LPS-induced inflammation.
Pseudomonas, Gram-negative bacteria, has been recognized as a common pathogen associated with respiratory infections in various clinical settings. It is a common cause of noscomical infection in hospitalized and immune-compromised patients [11, 17] , and a major cause of Pseudomonas pneumonia in cystic fibrosis patient [26] . Pseudomonas infection sometime causes persistent infection in patients, in the state of which anti-bacterial treatments are no longer effective. The bacteria harbor various inflammatory molecules on their surface. Along with LPS, for instance, they have polar pili that are involved in attachment to host cells and stimulate TLR2 signaling [21] . Pseudomonas also contains flagella that enable them to move around, which induces TLR5 signaling [1] . Therefore, it is likely that the bacterial infection activates a battery of TLR signaling cascades simultaneously, causing a massive inflammation in the lung. It is, however, notable that Pseudomonas infection to the lung induces more PGD2 over PGE2, which makes the infection self-limited. [20] . This is likely associated with the fact that Pseudomonas contains various antigens that might activate various TLR signaling cascades at the same time [19] . Given our results showing that LPS induced the production of PGE2 over PGD2, it is possible that while LPS induces the production of PGE2, other signaling cascades activated by Pseudomonas antigens combinatorially contribute to higher production of PGD2 over PGE2. It is conceivable that this is a part of defense strategies of the host immune system that diverts, or suppresses, an otherwise massive inflammation by tipping the balance of PGD2 and PGE2 to produce more anti-inflammatory PGD2.
It is not clear why we could not find any difference in expressions of L-PGDS and mPGES-1 by LPS treatment between two alveolar macrophages, MH-S and primary alveolar macrophages, although the profiles of PGD2 and PGE2 in those cell types were quite different. One possibility is that differential levels of mRNA of L-PGDS and mPEGS-1 lead to the imparity in the amounts of PGD2 and PGE2. However, it is noteworthy that PGD2 and PGE2 are highly unstable and the amounts of these prostanoids at a given time are correlated with the activities of the enzymes that are responsible for the production of the prostanoids. Thus, it is likely that the amounts and activities, but not the level of mRNA, of the enzymes are determining factor for the levels of the prostanoids. Our study also ruled out the possibility that COX-2 expression and PGH2 production affect the levels of L-PGDS and mPGES-1 and thereby determine the ratio of PGD2 and PGE2 because, as the results in Fig. 3 , the absence of COX-2 and presumably a basal level of PGH2 did not affect the expression of L-PGDS and mPGES-1. Although it is possible that COX-1, constitutively expressed in most cell types, affect the expression of L-PGDS and mPGES-1, a plethora of publications have consistently reported that COX-2 is the major COX enzyme in the inflammatory milieu. However, it is conceivable that, although having similar levels of L-PGDS and mPGES-1 proteins, MH-S and primary alveolar macrophages might have different expression profiles of enzymes catabolizing the prostanoids, by which a particular prostanoid was converted to its derivatives more rapidly and thus detected lower than the other prostanoid. While we do not understand the precise mechanism that governs the differential productions of PGD2 and PGE2, it is notable that the ratio of the two molecules in alveolar macrophages is similar to that of the lung. Thus, it is possible that alveolar macrophages isolated from a patient can be used as a parameter of whether or not infection by a type of bacteria will be self-limited or harmful to the patient.
In this study, we searched the mechanism that controls the ratio of PGD2 and PGE2 in the inflamed lung. We found that, unlike inflammation caused by Pseudomonas bacterial infection, lung inflammation induced by LPS produced more PGE2 over PGD2. Analysis of primary alveolar macrophages indicated that this was not due to differential expressions of L-PGDS and mPGES-1. Our results suggest that there is a potential correlation in the profiles of PGD2 and PGE2 between the lung and primary alveolar macrophages. Our results could provide a tool to predict whether a bacterial infection is self-limited or progressively inflammatory.
